Barclays analyst Peter Lawson downgraded Prelude Therapeutics (NASDAQ: PRLD) from Equalweight to Underweight with a price target of $3.00.The analyst ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE